ADC Therapeutics SA (ADCT)

NYSE: ADCT · Real-Time Price · USD

4.880

+0.080 (1.67%)

At close: Mar 11, 2026, 4:00 PM EDT

4.960

+0.080 (1.64%)

After-hours: Mar 11, 2026, 7:56 PM EDT

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
Development and Commercialization of Targeted ADC Cancer Therapies			69.56M	209.91M	33.92M		2.34M	1.14M
Development and Commercialization of Targeted ADC Cancer Therapies Growth			-66.86%	518.89%	-		105.26%	-36.77%
Total			69.56M	209.91M	33.92M		2.34M	1.14M
Total Growth			-66.86%	518.89%	-		105.26%	-36.77%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017
United States			69.06M	74.91M	-		-	-
United States Growth			-7.81%	-	-		-	-
Europe, The Middle East and Africa			498.00K	105.00M	-		-	-
Europe, The Middle East and Africa Growth			-99.53%	-	-		-	-
Switzerland			-	-	-		2.34M	1.14M
Switzerland Growth			-	-	-		105.26%	-
Japan			-	30.00M	-		-	-
Total			69.56M	209.91M	-		2.34M	1.14M
Total Growth			-66.86%	-	-		105.26%	-

Source: S&P Global Market Intelligence.